HC Wainwright analyst Robert Burns has lowered the price target for Nurix Therapeutics Inc (NASDAQ:NRIX) with a Buy rating.
Considering higher operating expenses moving forward while also decreasing the terminal growth rate to 1% from the prior 2% and raising the discount rate to 12% from the prior 11%, the analysts have lowered the price target from $53 to $33.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased